Clinical Trials Directory

Trials / Unknown

UnknownNCT05786183

Rapid Technique for the Detection of Intestinal Anti-transglutaminase Antibodies

Diagnostic Accuracy of a Rapid Technique for the Detection of Intestinal Anti-transglutaminase Antibodies to Enable a Real Time Diagnosis of Celiac Disease

Status
Unknown
Phase
Study type
Observational
Enrollment
163 (estimated)
Sponsor
IRCCS Burlo Garofolo · Academic / Other
Sex
All
Age
1 Year – 22 Years
Healthy volunteers
Not accepted

Summary

Intestinal Celiac Disease (CD)-antibodies have been described as the best marker to reveal progression toward villous atrophy and could become the diagnostic marker to make prompt diagnosis in the wide clinical spectrum of CD reducing the delay in diagnosis and treatment. The introduction of either anti-endomysial antibodies (EMA) assay or rapid anti-Transglutaminase 2 (TG2) test on supernatant of mechanically lysed biopsy samples in the clinical practice would improve the diagnosis of CD, especially in clinically challenging scenarios. The availability of an accurate test for identifying intestinal CD-antibodies that do not need the culture of intestinal biopsy is less expensive, less time consuming and easier to perform would facilitate the implementation of such technology outside research laboratories, and enable the diagnosis of CD at the end of Gastrointestinal Endoscopy (GIE).

Conditions

Timeline

Start date
2020-02-15
Primary completion
2024-03-15
Completion
2024-03-15
First posted
2023-03-27
Last updated
2023-03-27

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05786183. Inclusion in this directory is not an endorsement.

Rapid Technique for the Detection of Intestinal Anti-transglutaminase Antibodies (NCT05786183) · Clinical Trials Directory